These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 28604164)

  • 1. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.
    Mogasale V; Ramani E; Park IY; Lee JS
    Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries.
    Debellut F; Hendrix N; Pitzer VE; Neuzil KM; Constenla D; Bar-Zeev N; Marfin A; Pecenka C
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S154-S160. PubMed ID: 30845321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country Introduction.
    Soble A; Patel Z; Sosler S; Hampton L; Johnson H
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S160-S164. PubMed ID: 32725236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.
    Antillón M; Bilcke J; Paltiel AD; Pitzer VE
    Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of Typhoid Conjugate Vaccines in Africa and Asia.
    Neuzil KM; Pollard AJ; Marfin AA
    Clin Infect Dis; 2019 Feb; 68(Suppl 1):S27-S30. PubMed ID: 30767005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.
    Shakya M; Neuzil KM; Pollard AJ
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S770-S774. PubMed ID: 34374785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward Control? The Prospects and Challenges of Typhoid Conjugate Vaccine Introduction.
    Carey ME; Diaz ZI; Broadstock M; Bailey R; Bentsi-Enchill AD; Larson HJ
    Clin Infect Dis; 2019 Oct; 69(Suppl 5):S408-S411. PubMed ID: 31612940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
    Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revised Global Typhoid Vaccination Policy.
    Bentsi-Enchill AD; Hombach J
    Clin Infect Dis; 2019 Feb; 68(Suppl 1):S31-S33. PubMed ID: 30767001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?
    Steele AD; Carey ME; Kumar S; MacLennan CA; Ma LF; Diaz Z; Zaidi AKM
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S185-S190. PubMed ID: 32725223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
    Theiss-Nyland K; Shakya M; Colin-Jones R; Voysey M; Smith N; Karkey A; Dongol S; Pant D; Farooq YG; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S67-S73. PubMed ID: 30845329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK.
    Meiring JE; Gibani M;
    Vaccine; 2017 Sep; 35(38):5081-5088. PubMed ID: 28802757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of typhoid vaccination in India.
    Chauhan AS; Kapoor I; Rana SK; Kumar D; Gupta M; John J; Kang G; Prinja S
    Vaccine; 2021 Jul; 39(30):4089-4098. PubMed ID: 34120765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Date K; Shimpi R; Luby S; N R; Haldar P; Katkar A; Wannemuehler K; Mogasale V; Pallas S; Song D; Kunwar A; Loharikar A; Yewale V; Ahmed D; Horng L; Wilhelm E; Bahl S; Harvey P; Dutta S; Bhatnagar P
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S172-S178. PubMed ID: 32725235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines.
    Luthra K; Watts E; Debellut F; Pecenka C; Bar-Zeev N; Constenla D
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S83-S95. PubMed ID: 30845334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Can the Typhoid Fever Surveillance in Africa and the Severe Typhoid Fever in Africa Programs Contribute to the Introduction of Typhoid Conjugate Vaccines?
    Jeon HJ; Im J; Haselbeck A; Holm M; Rakotozandrindrainy R; Bassiahi AS; Panzner U; Mogeni OD; Seo HJ; Lunguya O; Jacobs J; Okeke IN; Terferi M; Owusu-Dabo E; Dougan G; Carey M; Steele AD; Kim JH; Clemens JD; Andrews JR; Park SE; Baker S; Marks F
    Clin Infect Dis; 2019 Oct; 69(Suppl 6):S417-S421. PubMed ID: 31665772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.